Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Roche Diagnostics...

    Roche Diagnostics India looks at 15 per cent IVD market share in 2 years

    Written by Ruby Khatun Khatun Published On 2017-09-04T10:30:21+05:30  |  Updated On 4 Sept 2017 10:30 AM IST
    Roche Diagnostics India looks at 15 per cent IVD market share in 2 years

    New Delhi: Roche Diagnostics India is aiming at 15 per cent share of the in-vitro diagnostics market in the next two years as part of its growth plans in the country.


    Roche Diagnostics is part of Swiss healthcare major Roche. It sells devices and equipment to labs and hospitals and is mainly present in the business-to-business space.


    "We are planning to have around 15 per cent of the market share in in-vitro diagnostics segment in India in next two years," Roche Diagnostics India & Neighbouring Markets MD Shravan Subramanyam told.


    The goal is to take a little bit of market share from the unorganised sector and grow the company's share of the market. The IVD industry in India is approximately worth Rs 5,000 crore, he added.


    In-vitro diagnostics are tests that can detect diseases, conditions or infections. Some tests are used in the laboratory or other health professional settings while others are for use at home.


    "We are also seeing consolidation of our customers, that is labs, and we would like to access tier II and tier III cities and rural markets through them and get a larger piece of the diagnostics market," Subramanyam said.


    From a strategic roadmap point of view, for the next five years, the company is looking at how to be relevant in India and so is focusing on areas such as women's health, non-communicable diseases like diabetes, cardio vascular diseases, cancer and wellness segments, he added.


    "But as India still has a very high burden of infectious diseases, we will continue to be in the space of infectious diseases," Subramanyam said.


    When asked if the company is planning to open a manufacturing or research and development facility in India, he said nothing in this direction was being planned at the moment.


    "Our focus is on digitising pathological labs, skill building amongst existing lab technicians and ensuring that the infrastructure is suitable for world class diagnostic tests to be launched in India," Subramanyam said.


    India is definitely a significant market for the company. It is one of the high growth markets in Asia-Pacific, he added.


    Roche Diagnostics India started its operations in January 2002 and provides diagnostic testing for early detection, evaluation and monitoring of diseases in the country. Currently, it is estimated to have around 14 per cent of the in vitro diagnostics market share in India.

    cancercardio vascular diseasesdiabetesequipmentsHealthcarein-vitro diagnostics marketIVDmarketRocheRoche Diagnostics IndiashareShravan Subramanyam
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok